Advertisement

Phloretin Inhibits the Human Prostate Cancer Cells Through the Generation of Reactive Oxygen Species

  • Ukjin Kim
  • C-Yoon Kim
  • Ji Min Lee
  • Hanseul Oh
  • Bokyeong Ryu
  • Jin Kim
  • Jae-Hak ParkEmail author
Original Article
  • 67 Downloads

Abstract

Phloretin is a flavonoid with known anticancer activities. However, we do not fully understand how phloretin mitigates prostate cancer on the molecular level. In the present study, we examined changes in proliferation, colony formation, and migration after phloretin treatment in human prostate cancer cells PC3 and DU145. We measured reactive oxygen species (ROS) and gene expression. Phloretin increased ROS and suppressed cell proliferation, migration, and colony formation in both cell lines. Additionally, phloretin treatment increased oxidative stress, as demonstrated through lower antioxidant enzymes (catalase, SOD2, Gpx1, Gpx3). In addition, their regulator CISD2 decreased in expression. We also found that increased ROS significantly downregulated multiple components of the Wnt/β-catenin signaling pathway (β-catenin, TCF4, FoxA2, c-Myc) and Twist1. Thus, anticancer activity of phloretin against human prostate cancer cells occurs through generating ROS to influence Wnt/β-catenin signaling. The results of this study suggest that phloretin has a therapeutic effect on prostate cancer in vitro, inhibiting the proliferation and migration of cancer cell lines PC3 and DU145. The mechanism of phloretin appears to be increasing ROS production. We thus recommend phloretin as a promising anticancer therapeutic agent.

Keywords

Phloretin Prostate cancer ROS Redox homeostasis Wnt/β-catenin signaling 

Notes

Author Contributions

Jae-Hak Park conceived and designed the experiments and is GUARANTOR for the article. Ukjin Kim, C-Yoon Kim, Ji Min Lee, Hanseul Oh, Bokyeong Ryu and Jin Kim performed experiments. Ukjin Kim analyzed the data and wrote the manuscript.

Funding Information

This study was supported by NRF (National Research Foundation of Korea) Grant funded by the Korean Government (NRF-2017-Global Ph.D. Fellowship Program) and partially supported by the Research Institute for Veterinary Science, BK21 PLUS Program for Creative Veterinary Science Research, Seoul National University.

Compliance with Ethical Standards

Conflict of Interest

None of the authors declare competing financial interests.

References

  1. 1.
    Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone A-M (2015) Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 107(6):djv048CrossRefGoogle Scholar
  2. 2.
    Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61(6):1079–1092CrossRefGoogle Scholar
  3. 3.
    Khandrika L, Kumar B, Koul S, Maroni P, Koul HK (2009) Oxidative stress in prostate cancer. Cancer Lett 282(2):125–136CrossRefGoogle Scholar
  4. 4.
    Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11(2):85–95CrossRefGoogle Scholar
  5. 5.
    Korswagen HC (2006) Regulation of the Wnt/β-catenin pathway by redox signaling. Dev Cell 10(6):687–688CrossRefGoogle Scholar
  6. 6.
    Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM, Taketo MM, Wills M, Matusik RJ (2009) Activation of β-catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 69(3):249–262CrossRefGoogle Scholar
  7. 7.
    Miller JR (2001) The wnts. Genome Biol 3(1):reviews3001. 3001CrossRefGoogle Scholar
  8. 8.
    Chesire DR, Ewing CM, Gage WR, Isaacs WB (2002) In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene 21(17):2679–2694CrossRefGoogle Scholar
  9. 9.
    Shin SY, Kim CG, Jho E-H, Rho M-S, Kim YS, Kim Y-H, Lee YH (2004) Hydrogen peroxide negatively modulates Wnt signaling through downregulation of β-catenin. Cancer Lett 212(2):225–231CrossRefGoogle Scholar
  10. 10.
    Boyer J, Liu RH (2004) Apple phytochemicals and their health benefits. Nutr J 3(1):5CrossRefGoogle Scholar
  11. 11.
    Devi MA, Das N (1993) In vitro effects of natural plant polyphenols on the proliferation of normal and abnormal human lymphocytes and their secretions of interleukin-2. Cancer Lett 69(3):191–196CrossRefGoogle Scholar
  12. 12.
    Zhu S-P, Liu G, Wu X-T, Chen F-X, Liu J-Q, Zhou Z-H, Zhang J-F, Fei S-J (2013) The effect of phloretin on human γδ T cells killing colon cancer SW-1116 cells. Int Immunopharmacol 15(1):6–14CrossRefGoogle Scholar
  13. 13.
    Nelson J, Falk R (1992) The efficacy of phloridzin and phloretin on tumor cell growth. Anticancer Res 13(6A):2287–2292Google Scholar
  14. 14.
    Kypta RM, Waxman J (2012) Wnt/β-catenin signalling in prostate cancer. Nature Reviews Urology 9(8):418–428CrossRefGoogle Scholar
  15. 15.
    Prasannaraj G, Sahi SV, Benelli G, Venkatachalam P (2017) Coating with active Phytomolecules enhances anticancer activity of bio-engineered ag Nanocomplex. J Clust Sci 28(4):2349–2367CrossRefGoogle Scholar
  16. 16.
    Priyadharshini RI, Prasannaraj G, Geetha N, Venkatachalam P (2014) Microwave-mediated extracellular synthesis of metallic silver and zinc oxide nanoparticles using macro-algae (Gracilaria edulis) extracts and its anticancer activity against human PC3 cell lines. Appl Biochem Biotechnol 174(8):2777–2790CrossRefGoogle Scholar
  17. 17.
    Liu Y, Fan C, Pu L, Wei C, Jin H, Teng Y, Zhao M, Yu ACH, Jiang F, Shu J (2016) Phloretin induces cell cycle arrest and apoptosis of human glioblastoma cells through the generation of reactive oxygen species. J Neuro-Oncol 128(2):217–223CrossRefGoogle Scholar
  18. 18.
    Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, Estaquio C, Hercberg S (2005) Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU. VI. MAX trial. Int J Cancer 116(2):182–186CrossRefGoogle Scholar
  19. 19.
    Kim J, Kim J, Bae J-S (2016) ROS homeostasis and metabolism: a critical liaison for cancer therapy. Exp Mol Med 48(11):e269CrossRefGoogle Scholar
  20. 20.
    Chang SN, Lee JM, Oh H, Park JH (2016) Glutathione peroxidase 3 inhibits prostate tumorigenesis in TRAMP mice. Prostate 76(15):1387–1398CrossRefGoogle Scholar
  21. 21.
    Lill R (2009) Function and biogenesis of iron–Sulphur proteins. Nature 460(7257):831–838CrossRefGoogle Scholar
  22. 22.
    Chen Y-F, Kao C-H, Chen Y-T, Wang C-H, Wu C-Y, Tsai C-Y, Liu F-C, Yang C-W, Wei Y-H, Hsu M-T (2009) Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice. Genes Dev 23(10):1183–1194CrossRefGoogle Scholar
  23. 23.
    Chang NC, Nguyen M, Bourdon J, Risse P-A, Martin J, Danialou G, Rizzuto R, Petrof BJ, Shore GC (2012) Bcl-2-associated autophagy regulator Naf-1 required for maintenance of skeletal muscle. Hum Mol Genet 21(10):2277–2287CrossRefGoogle Scholar
  24. 24.
    Li S-M, Chen C-H, Chen Y-W, Yen Y-C, Fang W-T, Tsai F-Y, Chang J-L, Shen Y-Y, Huang S-F, Chuu C-P (2017) Upregulation of CISD2 augments ROS homeostasis and contributes to tumorigenesis and poor prognosis of lung adenocarcinoma. Sci Rep 7(1):11893CrossRefGoogle Scholar
  25. 25.
    Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C (2005) Loss-of-function of Nkx3. 1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 65(15):6773–6779CrossRefGoogle Scholar
  26. 26.
    Prendergast GC (1999) Mechanisms of apoptosis by c-Myc. Oncogene 18(19):2967–2987CrossRefGoogle Scholar
  27. 27.
    Cassinelli G, Supino R, Zuco V, Lanzi C, Scovassi AI, Semple SC, Zunino F (2004) Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel. Biochem Pharmacol 68(5):923–931CrossRefGoogle Scholar
  28. 28.
    Li Q, Dang CV (1999) C-Myc overexpression uncouples DNA replication from mitosis. Mol Cell Biol 19(8):5339–5351CrossRefGoogle Scholar
  29. 29.
    Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F (2013) The twist box domain is required for Twist1-induced prostate cancer metastasis. Molecular Cancer Research:molcanres. 0218.2013Google Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  1. 1.Department of Laboratory Animal Medicine, Research Institute for Veterinary Science, BK21 PLUS Program for Creative Veterinary Science Research, College of Veterinary MedicineSeoul National UniversitySeoulRepublic of Korea
  2. 2.Department of Stem Cell Biology, School of MedicineKonkuk UniversitySeoulRepublic of Korea
  3. 3.National Primate Research CenterKorea Research Institute of Bioscience and BiotechnologyCheongjuRepublic of Korea

Personalised recommendations